P16 is a tumor suppressor protein implicated in serous papillary endometrial carcinoma. Evidence from previous trials indicates that it may be used as a diagnostic biomarker distinguishing this disease from endometrioid endometrial cancer. Additional evidence points to its prognostic value. The current study will evaluate p16 both as a diagnostic tool for serous papillary endometrial cancer and as a prognostic biomarker. following anonymization, histology blocks will be microtomed and stained for P16 and P53 proteins. Blocks from endometrioid endometrial cancer will be used as a control group.
Study Type
OBSERVATIONAL
Enrollment
62
Rambam Medical Center
Haifa, Israel
Overall survival
Time frame: last followup (2-10 years)
progression free survival
Time frame: Current follow up (2-10 years)
correlation of P16 stain with histological diagnosis
Time frame: at last follow up (2-10 years)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.